According to the recent study the FLT3 inhibitor market is projected to reach an estimated $XX billion by 2028 from $XX billion in 2023, at a CAGR of 4% to 6% from 2023 to 2028. Growth in this market is primarily driven by introduction of novel products, increasing incidence of acute myeloid leukemia, and rising frequency of clinical trials.